Evidence map›Paper›PMID 41954176›Full record

ArticleChemistryOpen2026

Safe by Design Flow Technology for Diazoacetonitrile Generation and Direct Conversion to Pyrazoles.

Dušan Bošković, Stefan Loebbecke, Calogero Giancarlo Piscopo, Ligia Johanna Radulescu, Maud Schwarzer

Abstract read
In one paragraph

Article in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dušan BoškovićEnergetic Materials Department, Fraunhofer Institute for Chemical Technology ICT, Pfinztal, Germany.ORCID https://orcid.org/0009-0001-6563-6611
Stefan LoebbeckeEnergetic Materials Department, Fraunhofer Institute for Chemical Technology ICT, Pfinztal, Germany.
Calogero Giancarlo PiscopoEnergetic Materials Department, Fraunhofer Institute for Chemical Technology ICT, Pfinztal, Germany.ORCID https://orcid.org/0000-0003-0601-3606
Ligia Johanna RadulescuEnergetic Materials Department, Fraunhofer Institute for Chemical Technology ICT, Pfinztal, Germany.
Maud SchwarzerEnergetic Materials Department, Fraunhofer Institute for Chemical Technology ICT, Pfinztal, Germany.

Funding

Fraunhofer-Gesellschaft Lighthouse project ShaPID
6 · The paper itself

Abstract

Diazo compounds enable short and efficient synthetic routes but their broader adoption is limited by hazards associated with their preparation, storage, and handling. Here, a safe by design continuous flow process is presented in which diazoacetonitrile (DAN) is generated in aqueous solution, transferred into an organic phase with minimal hold up, and immediately consumed in a telescoped [3 + 2] cycloaddition with activated alkynes to obtain 3 cyano 1H pyrazoles. Operating windows for solvent choice, temperature, residence time, and pressure are established, and the influence of added HCl on nitrosation efficiency and DAN decay is observed. Dichloromethane and benzonitrile are compared as extraction and reaction media: benzonitrile enables higher organic phase DAN concentrations, whereas dichloromethane facilitates isolation. Under optimized conditions, NMR yields of ∼60%-80% are obtained for reactions with methyl propiolate, and a 2 h telescoped run affords a 37% isolated yield after recrystallization. The workflow prevents isolation or accumulation of DAN, improving the safety of processes involving this energetic intermediate and illustrating how continuous flow and biphasic extraction can support greener synthesis by avoiding reaction steps.

Indexed as

continuous flowdiazoacetonitrilegreen methodshazardous chemistrypyrazole

Identifiers

PMID41954176
PMCPMC13063248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.